Introduced by Committee on Human Services

Date:

Subject: Human services; opioid use disorder; treatment; recovery

Statement of purpose of bill as introduced: This bill proposes to: (1) expand the locations in which an organized community-based needle exchange program can operate; (2) prohibit a health insurance plan from requiring prior authorization during the first 60 days of initiating medication-assisted treatment when the prescribed medication is for opioid or opiate withdrawal; (3) establish the Overdose Prevention Site Working Group; and (4) appropriate funds for three pilot programs specific to mobile medication-assisted treatment, supports for justice-involved individuals, and overdose emergency response support.

An act relating to opioid overdose response services

It is hereby enacted by the General Assembly of the State of Vermont:

*** Operation of Syringe Service Programs ***

Sec. 1. 18 V.S.A. § 4475 is amended to read:

§ 4475. DEFINITIONS

(a)(1) The term “drug paraphernalia” means all equipment, products, devices, and materials of any kind that are used, or promoted for use or
designed for use, in planting, propagating, cultivating, growing, harvesting,
manufacturing, compounding, converting, producing, processing, preparing,
testing, analyzing, packaging, repackaging, storing, containing, concealing,
injecting, ingesting, inhaling, or otherwise introducing into the human body a
regulated drug in violation of chapter 84 of this title. “Drug paraphernalia”
does not include needles and syringes, or other harm reduction supplies
distributed or possessed as part of an organized community-based needle
exchange program.

(2) “Organized community-based needle exchange program” means a
program approved by the Commissioner of Health under section 4478 of this
title, the purpose of which is to provide access to clean needles and syringes,
and which is operated by an AIDS service organization, a substance abuse
treatment provider, or a licensed health care provider or facility. Such
programs shall be operated in a manner that is consistent with the provisions of
10 V.S.A. chapter 159 (waste management; hazardous waste), and any other
applicable laws.

* * *

Sec. 2. REPORT; NEEDLE EXCHANGE PROGRAM GUIDELINES

On or before January 1, 2023, the Department of Health shall submit a
written report to the House Committee on Human Services and to the Senate
Committee on Health and Welfare on updates to the needle exchange program
operating guidelines required pursuant to 18 V.S.A. § 4478 that reflect current
practice and consideration of the feasibility and costs of designating
organizations to deliver peer-operated needle exchange.

*** Prior Authorization for Medication-Assisted Treatment

Effective July 1, 2022 ***

Sec. 3. 18 V.S.A. § 4750 is amended to read:

§ 4750. DEFINITIONS

As used in this chapter:

(1) “Health insurance plan” has the same meaning as in 8 V.S.A.
§ 4089b means any health insurance policy or health benefit plan offered by a
health insurer, as defined in section 9402 of this title, as well as Medicaid and
any other public health care assistance program offered or administered by the
State or by any subdivision or instrumentality of the State. The term does not
include policies or plans providing coverage for a specified disease or other
limited benefit coverage.

***

Sec. 4. 18 V.S.A. § 4754 is amended to read:

§ 4754. LIMITATION ON PRIOR AUTHORIZATION REQUIREMENTS

(a) A health insurance plan shall not require prior authorization for
prescription drugs for a patient who is receiving medication-assisted treatment
if the dosage prescribed is within the U.S. Food and Drug Administration’s
dosing recommendations or during the first 60 days of medication-assisted
treatment when the medication is prescribed to an individual.

(b) A health insurance plan shall cover the following medications without
requiring prior authorization:

(1) one medication within each therapeutic class of medication approved
by the U.S. Food and Drug Administration for the treatment of substance use
disorders; and

(2) one medication that is a formulation of a buprenorphine mono-
product approved by the U.S. Food and Drug Administration for the treatment
of substance use disorders.

(c) A health insurance plan shall not require prior authorization for all
counseling and behavioral therapies associated with medication-assisted
treatment for a patient who is receiving medication-assisted treatment.

* * * Prior Authorization for Medication-Assisted Treatment

Effective July 1, 2025 * * *

Sec. 5. 18 V.S.A. § 4750 is amended to read:

§ 4750. DEFINITIONS

As used in this chapter:

(1) “Health insurance plan” means any health insurance policy or health
benefit plan offered by a health insurer, as defined in section 9402 of this title,
as well as Medicaid and any other public health care assistance program.
offered or administered by the State or by any subdivision or instrumentality of the State. The term does not include policies or plans providing coverage for a specified disease or other limited benefit coverage has the same meaning as in 8 V.S.A. § 4089b.

* * *

Sec. 6. 18 V.S.A. § 4754 is amended to read:

§ 4754. LIMITATION ON PRIOR AUTHORIZATION REQUIREMENTS

(a) A health insurance plan shall not require prior authorization for prescription drugs for a patient who is receiving medication-assisted treatment if the dosage prescribed is within the U.S. Food and Drug Administration’s dosing recommendations or during the first 60 days of medication-assisted treatment when the medication is prescribed to a patient for opioid or opiate withdrawal.

(b) A health insurance plan shall cover the following medications without requiring prior authorization:

(1) one medication within each therapeutic class of medication approved by the U.S. Food and Drug Administration for the treatment of substance use disorders; and

(2) one medication that is a formulation of a buprenorphine mono-product approved by the U.S. Food and Drug Administration for the treatment of substance use disorders.
A health insurance plan shall not require prior authorization for all counseling and behavioral therapies associated with medication-assisted treatment for a patient who is receiving medication-assisted treatment.

* * * Report on Prior Authorization for Medication-Assisted Treatment in Medicaid * * *

Sec. 7. REPORTS; PRIOR AUTHORIZATION FOR MEDICATION-ASSISTED TREATMENT; MEDICAID

On or before February 1, 2023, 2024, and 2025, the Department of Vermont Health Access shall report to the House Committees on Health Care and on Human Services and to the Senate Committee on Health and Welfare regarding prior authorization processes for medication-assisted treatment in Vermont’s Medicaid program during the previous calendar year, including:

(1) which medications required prior authorization;

(2) how many prior authorization requests the Department received and, of these, how many were approved and denied; and

(3) the average and longest length of time the Department took to process a prior authorization request.

* * * Overdose Prevention Site Working Group * * *

Sec. 8. OVERDOSE PREVENTION SITE WORKING GROUP

(a) Creation. In recognition of the rapid increase in overdose deaths across the State, with a record number of opioid-related deaths in 2021, there is
created the Overdose Prevention Site Working Group to identify the feasibility and liability of implementing overdose prevention sites in Vermont.

(b) Membership. The Working Group shall be composed of the following members:

(1) the Commissioner of Health or designee;

(2) the Commissioner of Public Safety or designee;

(3) a representative, appointed by the State’s Attorneys Offices;

(4) two representatives, appointed by the Vermont League of Cities and Towns, from different regions of the State;

(5) two individuals with lived experience of opioid use disorder, including at least one of whom is in recovery; one member appointed by the Howard Center’s Safe Recovery program; and one member appointed by the Vermont Association of Mental Health and Addiction Recovery;

(6) the Program Director from the Consortium on Substance Use;

(7) the Program Director from the Howard Center’s Safe Recovery program;

(8) a primary care prescriber with experience providing medication-assisted treatment within the hub-and-spoke model, appointed by the Clinical Director of Alcohol and Drug Abuse Programs; and

(9) an emergency department physician, appointed by the Vermont Medical Society.
(c) Powers and duties. The Working Group shall:

1. conduct an inventory of overdose prevention sites nationally;
2. identify the feasibility and liability of both publicly funded and privately funded overdose prevention sites;
3. make recommendations on municipal and local actions necessary to implement overdose prevention sites; and
4. make recommendations on executive and legislative actions necessary to implement overdose prevention sites, if any.

(d) Assistance. The Working Group shall have the administrative, technical, and legal assistance of the Department of Health.

(e) Report. On or before November 15, 2023, the Working Group shall submit a written report to the House Committee on Human Services and the Senate Committee on Health and Welfare with its findings and any recommendations for legislative action.

(f) Meetings.

1. The Commissioner of Health or designee shall call the first meeting of the Working Group to occur on or before September 15, 2022.
2. The Committee shall select a chair from among its members at the first meeting.
3. A majority of the membership shall constitute a quorum.
(g) Compensation and reimbursement. Members of the Working Group shall be entitled to per diem compensation and reimbursement of expenses as permitted under 32 V.S.A. § 1010 for not more than eight meetings. These payments shall be made from monies appropriated to the Department of Health.

(h) As used in this section, “overdose prevention site” means a facility where individuals can use previously acquired regulated drugs as defined in 18 V.S.A. § 4201.

*** Pilot Programs ***

Sec. 9. PILOT PROGRAM; MOBILE MEDICATION-ASSISTED TREATMENT

In fiscal year 2023, $450,000.00 is appropriated from the General Fund to the Department of Health’s Division of Alcohol and Drug Abuse Programs for the purpose of awarding one or more grants for mobile medication-assisted treatment services in accordance with federal laws. The Division shall award grants based on an applicant’s ability to provide medication-assisted treatment, including methadone, to currently underserved areas of the State.

Sec. 10. PILOT PROGRAM; SUBSTANCE USE SUPPORT FOR JUSTICE-INVOLVED VERMONTERS

In fiscal year 2023, $250,000.00 is appropriated from the General Fund to the Department of Health’s Division of Alcohol and Drug Abuse Programs to
award one or more grants to an organization or organizations providing
substance use treatment counseling or substance use recovery support, or both,
for individuals within and transitioning out of the criminal justice system. The
Division shall award grants based on an applicant’s ability to accomplish the
following:

(1) provide justice-involved individuals with direct substance use
support services while incarcerated, such as through alcohol and drug abuse
counselors licensed pursuant to 26 V.S.A. chapter 62 or certified recovery
coaches, or both;

(2) support justice-involved individuals in their transition out of
incarceration, such as through warm handoffs to existing statewide resources
for substance use treatment or recovery; or

(3) provide long-term support for justice-involved individuals, such as
by coordinating peer support services or ongoing counseling post-
incarceration.

Sec. 11. PILOT PROGRAM; OVERDOSE EMERGENCY RESPONSE
SUPPORT

In fiscal year 2023, $180,000.00 is appropriated from the General Fund to
the Department of Health’s Division of Alcohol and Drug Abuse Programs to
award four equal grants to organizations to provide or facilitate connection to
substance use treatment, recovery, or harm reduction services at the time of
emergency response to overdose. The Division shall award grants based on an
applicant’s ability to support individuals at risk of fatal overdose by facilitating
warm handoffs to treatment, recovery, and harm reduction services through
coordination between public safety, emergency medical services, substance use
treatment and health care providers, and substance use recovery services.

*** Effective Dates ***

Sec. 12. EFFECTIVE DATES

This act shall take effect on July 1, 2022, except that Secs. 5 (definitions)
and 6 (limitation on prior authorization requirements) shall take effect on
July 1, 2025.